Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Lieping Chen, Xue Han
Journal of Clinical Investigation (2015) Vol. 125, Iss. 9, pp. 3384-3391
Open Access | Times Cited: 1308

Showing 1-25 of 1308 citing articles:

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Gang Chen, Alexander C. Huang, Wei Zhang, et al.
Nature (2018) Vol. 560, Iss. 7718, pp. 382-386
Open Access | Times Cited: 2327
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou, Jedd D. Wolchok, Lieping Chen
Science Translational Medicine (2016) Vol. 8, Iss. 328
Open Access | Times Cited: 2140
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab, Samaresh Sau, Rami M. Alzhrani, et al.
Frontiers in Pharmacology (2017) Vol. 8
Open Access | Times Cited: 1523
Comprehensive review of targeted therapy for colorectal cancer
Yuanhong Xie, Yingxuan Chen, Jing‐Yuan Fang
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 1316
Cancer immunotherapy: harnessing the immune system to battle cancer
Yiping Yang
Journal of Clinical Investigation (2015) Vol. 125, Iss. 9, pp. 3335-3337
Open Access | Times Cited: 1215
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Miguel F. Sanmamed, Lieping Chen
Cell (2018) Vol. 175, Iss. 2, pp. 313-326
Open Access | Times Cited: 1195
Radiotherapy and immunotherapy: a beneficial liaison?
Ralph R. Weichselbaum, Hua Liang, Liufu Deng, et al.
Nature Reviews Clinical Oncology (2017) Vol. 14, Iss. 6, pp. 365-379
Closed Access | Times Cited: 884
Targeting neoantigens to augment antitumour immunity
Mark Yarchoan, Burles A. Johnson, Eric R. Lutz, et al.
Nature reviews. Cancer (2017) Vol. 17, Iss. 4, pp. 209-222
Open Access | Times Cited: 881
The Cytosolic DNA-Sensing cGAS–STING Pathway in Cancer
John Kwon, Samuel F. Bakhoum
Cancer Discovery (2019) Vol. 10, Iss. 1, pp. 26-39
Open Access | Times Cited: 871
Mechanisms Controlling PD-L1 Expression in Cancer
Jong‐Ho Cha, Li-Chuan Chan, Chia‐Wei Li, et al.
Molecular Cell (2019) Vol. 76, Iss. 3, pp. 359-370
Open Access | Times Cited: 748
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
Jong‐Ho Cha, Wenhao Yang, Weiya Xia, et al.
Molecular Cell (2018) Vol. 71, Iss. 4, pp. 606-620.e7
Open Access | Times Cited: 643
Neoantigen vaccine: an emerging tumor immunotherapy
Peng Miao, Yongzhen Mo, Yian Wang, et al.
Molecular Cancer (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 563
Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
Jun Wang, Jingwei Sun, Linda N. Liu, et al.
Nature Medicine (2019) Vol. 25, Iss. 4, pp. 656-666
Open Access | Times Cited: 557
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Kabir A. Khan, Robert S. Kerbel
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 5, pp. 310-324
Closed Access | Times Cited: 530
Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy
Ying Zhang, Raj K. Kurupati, Ling Liu, et al.
Cancer Cell (2017) Vol. 32, Iss. 3, pp. 377-391.e9
Open Access | Times Cited: 513
Resistance to PD1/PDL1 checkpoint inhibition
Jake S. O’Donnell, Georgina V. Long, Richard A. Scolyer, et al.
Cancer Treatment Reviews (2016) Vol. 52, pp. 71-81
Closed Access | Times Cited: 508
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
Angeliki M. Stamatouli, Zoe Quandt, Ana Luisa Perdigoto, et al.
Diabetes (2018) Vol. 67, Iss. 8, pp. 1471-1480
Open Access | Times Cited: 491
IDH mutation in glioma: molecular mechanisms and potential therapeutic targets
Sue Han, Yang Liu, Sabrina J. Cai, et al.
British Journal of Cancer (2020) Vol. 122, Iss. 11, pp. 1580-1589
Open Access | Times Cited: 478
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Chia‐Wei Li, Seung-Oe Lim, Ezra M. Chung, et al.
Cancer Cell (2018) Vol. 33, Iss. 2, pp. 187-201.e10
Open Access | Times Cited: 477
PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
Haidong Tang, Yong Liang, Robert A. Anders, et al.
Journal of Clinical Investigation (2018) Vol. 128, Iss. 2, pp. 580-588
Open Access | Times Cited: 467
In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy
Chao Wang, Wujin Sun, Yanqi Ye, et al.
Nature Biomedical Engineering (2017) Vol. 1, Iss. 2
Closed Access | Times Cited: 464
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
Thomas A. Mace, Reena Shakya, Jason R. Pitarresi, et al.
Gut (2016) Vol. 67, Iss. 2, pp. 320-332
Open Access | Times Cited: 447
Fates of CD8+ T cells in Tumor Microenvironment
Nomathamsanqa Resegofetse Maimela, Shasha Liu, Yi Zhang
Computational and Structural Biotechnology Journal (2018) Vol. 17, pp. 1-13
Open Access | Times Cited: 421
COX2/mPGES1/PGE 2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells
Victor Prima, Lyudmila N. Kaliberova, Sergey A. Kaliberov, et al.
Proceedings of the National Academy of Sciences (2017) Vol. 114, Iss. 5, pp. 1117-1122
Open Access | Times Cited: 414
PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy
Fatemeh Karimi Dermani, Pouria Samadi, Golebagh Rahmani, et al.
Journal of Cellular Physiology (2018) Vol. 234, Iss. 2, pp. 1313-1325
Closed Access | Times Cited: 413
Page 1 - Next Page

Scroll to top